Feed / PVLA

Palvella Therapeutics, Inc.

PVLA

Healthcare · 149.96 +2.6% today

Participation confirmed · construction unavailableMarket checked 19 Aug, 15:55 GMT-4

Jodie situation report

Palvella Therapeutics, Inc.'s move is spreading beyond its market group.

No new filing conclusion is available. 23 of 23 group members are active now; 1 filing-linked outsider is moving with the group, and 0 of 5 directly disclosed connections are confirming.

Company+2.6% todayVolume comparison unavailable
Market group23 of 23 activeClinical Biotechnology · active
Disclosed network0 of 5 confirmingNo filing-linked name is confirming now
What would change this read
  • At least 15 of 23 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • BMRN remains aligned with the group in the next market snapshot.

Invalidation: The live read weakens if participation falls to 8 of 23 members or fewer.

Watch this read

Who this business touches

The relationships behind PVLA

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

LGNDLigand Pharmaceuticals IncorporatedpartnerMay 7, 2026

Under the Ligand Agreement, Ligand has made payments totaling $15.0 million to fund the development of QTORIN rapamycin.

NVSNovartis AGcompetitorMar 31, 2026

To the best of our knowledge, potential competitors with product candidates in development for serious, rare skin diseases and vascular malformations include Kaken Pharmaceutical Co., Ltd., Nobelpharma Co., Ltd., Novartis Pharmaceuticals, Protara Therapeutics…

QNRXFiling-linked namecompetitorMar 31, 2026

To the best of our knowledge, potential competitors with product candidates in development for serious, rare skin diseases and vascular malformations include Kaken Pharmaceutical Co., Ltd., Nobelpharma Co., Ltd., Novartis Pharmaceuticals, Protara Therapeutics…

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

PVLA is currently a Early Follower in the organic co-movement group Clinical Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.